The Effect of Early Insulin Therapy on Pancreatic β-Cell Function and Long-Term Glycemic Control in Newly Diagnosed Type 2 Diabetic Patients
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: Based on the results of well designed clinical studies, intensive insulin therapy has been established to improve glycemic control in newly diagnosed diabetes. However, discrepancies exist between the findings of clinical trials and experiences in general practice. Furthermore, the efficacy of an early insulin therapy (EIT) - commonly used in general practice - on long-term glycemic control has not been established. Therefore,we evaluated the effects of EIT on pancreatic β-cell function and glycemic control using insulin-based methods widely employed in general practice. Methods: We performed a retrospective cohort study that initially involved reviewing patients’ medical records. Following a thorough review, 61 patients who received either biphasic or prandial EIT at the time of diagnosis were enrolled. We then evaluated changes in β-cell function and glycemic control during a 48-month follow-up period. Results: Mean HbA1c decreased significantly as a result of EIT from 10.7 ± 1.8% to 6.2 ± 1.1% (p < 0.001). On average, 2.6 months was required to achieve an HbA1c value < 7%. EIT significantly improved the insulinogenic index. Glycemic control was well maintained for 48 months. More than 70% of patients were able to maintain glycemic control following lifestyle modifications or treatment with oral antidiabetic drugs. No significant differences were identified between patients receiving biphasic EIT and prandial EIT in terms of glycemic control or pancreatic β-cell function. Conclusions: Our results suggest that regardless of the method of delivery, EIT significantly improves β-cell function and facilitates long-term glycemic control in patients with newly diagnosed type 2 diabetes mellitus.(Korean J Intern Med 2010;25:273-281)
Abstract
Background/Aims: Based on the results of well designed clinical studies, intensive insulin therapy has been established to improve glycemic control in newly diagnosed diabetes. However, discrepancies exist between the findings of clinical trials and experiences in general practice. Furthermore, the efficacy of an early insulin therapy (EIT) - commonly used in general practice - on long-term glycemic control has not been established. Therefore,we evaluated the effects of EIT on pancreatic β-cell function and glycemic control using insulin-based methods widely employed in general practice. Methods: We performed a retrospective cohort study that initially involved reviewing patients’ medical records. Following a thorough review, 61 patients who received either biphasic or prandial EIT at the time of diagnosis were enrolled. We then evaluated changes in β-cell function and glycemic control during a 48-month follow-up period. Results: Mean HbA1c decreased significantly as a result of EIT from 10.7 ± 1.8% to 6.2 ± 1.1% (p < 0.001). On average, 2.6 months was required to achieve an HbA1c value < 7%. EIT significantly improved the insulinogenic index. Glycemic control was well maintained for 48 months. More than 70% of patients were able to maintain glycemic control following lifestyle modifications or treatment with oral antidiabetic drugs. No significant differences were identified between patients receiving biphasic EIT and prandial EIT in terms of glycemic control or pancreatic β-cell function. Conclusions: Our results suggest that regardless of the method of delivery, EIT significantly improves β-cell function and facilitates long-term glycemic control in patients with newly diagnosed type 2 diabetes mellitus.(Korean J Intern Med 2010;25:273-281)
참고문헌 (32)
- UK Prospective Diabetes Study (UKPDS) Group, "Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)", Lancet, 352, pp.837~853 (1998)
- UK Prospective Diabetes Study (UKPDS) Group, "Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)", Lancet, 352, pp.854~865 (1998)
- Kahn SE, "Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy", N Engl J Med, 355, pp.2427~2443 (2006)
- Weng J, "Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallelgroup trial", Lancet, 371, pp.1753~1760 (2008)
- Wajchenberg BL, "beta-cell failure in diabetes and preservation by clinical treatment", Endocr Rev, 28, pp.187~218 (2007)
- Ilkova H, "Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients by transient intensive insulin treatment", Diabetes Care, 20, pp.1353~1356 (1997)
- Li Y, "Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients is associated with improvement of beta-cell function", Diabetes Care, 27, pp.2597~2602 (2004)
- Ryan EA, "Short-term intensive insulin therapy in newly diagnosed type 2 diabetes", Diabetes Care, 27, pp.1028~1032 (2004)
- Matthews DR, "Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man", Diabetologia, 28, pp.412~419 (1985)
- Phillips DI, "Understanding oral glucose tolerance: comparison of glucose or insulin measurements during the oral glucose tolerance test with specific measurements of insulin resistance and insulin secretion", Diabet Med, 11, pp.286~292 (1994)
- WHO Expert Consultation, "Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies", Lancet, 363, pp.157~163 (2004)
- Nathan DM, "Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes", Diabetes Care, 29, pp.1963~1972 (2006)
- Hirao K, "Japan Diabetes Clinical Data Management Study Group. Six-month multicentric, open-label, randomized trial of twice-daily injections of biphasic insulin aspart 30 versus multiple daily injections of insulin aspart in Japanese type 2 diabetic patients (JDDM 11)", Diabetes Res Clin Pract, 79, pp.171~176 (2008)
- McFarlane SI, "Near-normoglycaemic remission in African-Americans with Type 2 diabetes mellitus is associated with recovery of beta cell function", Diabet Med, 18, pp.10~16 (2001)
- Retnakaran R, "Intensive insulin therapy in newly diagnosed type 2 diabetes", Lancet, 371, pp.1725~1726 (2008)
- Gleason CE, "Determinants of glucose toxicity and its reversibility in the pancreatic islet betacell line, HIT-T15", Am J Physiol Endocrinol Metab, 279, pp.E997~E1002 (2000)
- Yki-Järvinen H, "Clinical benefits and mechanisms of a sustained response to intermittent insulin therapy in type 2 diabetic patients with secondary drug failure", Am J Med, 84, pp.185~192 (1988)
- Samanta A, "The effect of short term intensive insulin therapy in non-insulin-dependent diabetics who had failed on sulphonylurea therapy", Diabetes Res, 3, pp.269~271 (1986)
- Glaser B, "Improved beta-cell function after intensive insulin treatment in severe non-insulin-dependent diabetes", Acta Endocrinol (Copenh), 118, pp.365~373 (1988)
- Turner RC, "Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group", JAMA, 281, pp.2005~2012 (1999)
- Hansen TK, "Intensive insulin therapy exerts antiinflammatory effects in critically ill patients and counteracts the adverse effect of low mannose-binding lectin levels", J Clin Endocrinol Metab, 88, pp.1082~1088 (2003)
- He QH, "Improvement of the function of islet beta and alpha cells by intervention against glucotoxicity: experiment with rats", Zhonghua Yi Xue Za Zhi, 88, pp.374~377 (2008)
- Garvey WT, "The effect of insulin treatment on insulin secretion and insulin action in type II diabetes mellitus", Diabetes, 34, pp.222~234 (1985)
- Rhee MK, "Patient adherence improves glycemic control", Diabetes Educ, 31, pp.240~250 (2005)
- Kennedy L, "GOAL AIC Team. Impact of active versus usual algorithmic titration of basal insulin and point-of-care versus laboratory measurement of HbA1c on glycemic control in patients with type 2 diabetes: the Glycemic Optimization with Algorithms and Labs at Point of Care (GOAL A1C) trial", Diabetes Care, 29, pp.1~8 (2006)
- Ovalle F, "Effect of rosiglitazone versus insulin on the pancreatic beta-cell function of subjects with type 2 diabetes", Diabetes Care, 27, pp.2585~2589 (2004)
- Alvarsson M, "Effects of insulin vs. glibenclamide in recently diagnosed patients with type 2 diabetes: a 4-year follow-up", Diabetes Obes Metab, 10, pp.421~429 (2008)
- Miller FG, "The therapeutic orientation to clinical trials", N Engl J Med, 348, pp.1383~1386 (2003)
- Appelbaum PS, "False hopes and best data: consent to research and the therapeutic misconception", Hastings Cent Rep, 17, pp.20~24 (1987)
- Lidz CW, "The therapeutic misconception: problems and solutions", Med Care, 40, pp.V55~V63 (2002)
- Miller PB, "Trust based obligations of the state and physician-researchers to patient-subjects", J Med Ethics, 32, pp.542~547 (2006)
- Charuvastra A, "Unconscious emotional reasoning and the therapeutic misconception", J Med Ethics, 34, pp.193~197 (2008)